Host STAT2/type I interferon axis controls tumor growth.
Int J Cancer
; 136(1): 117-26, 2015 Jan 01.
Article
de En
| MEDLINE
| ID: mdl-24895110
ABSTRACT
The role of STAT2 in mediating the antigrowth effects of type I interferon (IFN) is well-documented in vitro. Yet evidence of IFN-activated STAT2 as having tumor suppressor function in vivo and participation in antitumor immunity is lacking. Here we show in a syngeneic tumor transplantation model that STAT2 reduces tumor growth. Stat2(-/-) mice formed larger tumors compared to wild type (WT) mice. IFN-ß treatment of Stat2(-/-) mice did not cause tumor regression. Gene expression analysis revealed a small subset of immunomodulatory genes to be downregulated in tumors established in Stat2(-/-) mice. Additionally, we found tumor antigen cross-presentation by Stat2(-/-) dendritic cells to T cells to be impaired. Adoptive transfer of tumor antigen specific CD8(+) T cells primed by Stat2(-/-) dendritic cells into tumor-bearing Stat2(-/-) mice did not induce tumor regression with IFN-ß intervention. We observed that an increase in the number of CD4(+) and CD8(+) T cells in the draining lymph nodes of IFN-ß-treated tumor-bearing WT mice was absent in IFN-ß treated Stat2(-/-) mice. Thus our study provides evidence for further evaluation of STAT2 function in cancer patients receiving type I IFN based immunotherapy.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Mélanome expérimental
/
Interféron bêta
/
Charge tumorale
/
Facteur de transcription STAT-2
/
Tumeurs du poumon
/
Antinéoplasiques
Type d'étude:
Prognostic_studies
Limites:
Animals
Langue:
En
Journal:
Int J Cancer
Année:
2015
Type de document:
Article
Pays d'affiliation:
Panama